GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors
Sign Up to like & getrecommendations! Published in 2018 at "Nature Communications"
DOI: 10.1038/s41467-018-07644-6
Abstract: Mutant KRas is a significant driver of human oncogenesis and confers resistance to therapy, underscoring the need to develop approaches that disable mutant KRas-driven tumors. Because targeting KRas directly has proven difficult, identifying vulnerabilities specific… read more here.
Keywords: vivo growth; dependent tumors; mutant kras; kras dependent ... See more keywords